Sinopharm Covid-19 Vaccine | The Business Standard
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Sunday
January 29, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
SUNDAY, JANUARY 29, 2023

Sinopharm Covid-19 Vaccine

FILE PHOTO: A vial labelled "Sinopharm COVID-19 Vaccine" is seen in this illustration taken January 16, 2022. REUTERS/Dado Ruvic/Illustration
Coronavirus chronicle

Some Omicron sub-variants escaping antibodies from Sinopharm shot

A nurse holds a vial of China's Sinopharm coronavirus disease (COVID-19) vaccine at a health center in Caracas, Venezuela March 7, 2021. REUTERS/Leonardo Fernandez Viloria
Covid-19 in Bangladesh

Local production of Sinopharm vaccine uncertain

J&J, Sinopharm, Sputnik V shots weaker against Omicron, study shows
Coronavirus chronicle

J&J, Sinopharm, Sputnik V shots weaker against Omicron, study shows

A nurse holds a vial of China's Sinopharm coronavirus disease (COVID-19) vaccine at a health center in Caracas, Venezuela March 7, 2021. REUTERS/Leonardo Fernandez Viloria
Covid-19 in Bangladesh

More 55 lakh Sinopharm jabs arrive 

File photo
Bangladesh

More 50 lakh Sinopharm vaccine doses arrive 

Photo: Reuters
Covid-19 in Bangladesh

50 lakh more doses of Sinopharm vaccine reach Dhaka

A sign of Sinopharm is seen at the 2020 China International Fair for Trade in Services (CIFTIS), following the COVID-19 outbreak, in Beijing, China September 5, 2020. REUTERS/Tingshu Wang
Coronavirus chronicle

Chinese vaccines are welcomed by its neighbours, WHY?

Photo: Courtesy
Covid-19 in Bangladesh

‘Already applied with WHO, now awaiting approval’: Minister on jabbing schoolgoers

A sign of Sinopharm is seen at the 2020 China International Fair for Trade in Services (CIFTIS), following the COVID-19 outbreak, in Beijing, China September 5, 2020. REUTERS/Tingshu Wang
Coronavirus chronicle

Peru study finds Sinopharm Covid vaccine 50.4% effective against infections

A nurse holds a vial of China's Sinopharm coronavirus disease (COVID-19) vaccine at a health center in Caracas, Venezuela March 7, 2021. REUTERS/Leonardo Fernandez Viloria
Covid-19 in Bangladesh

Another 1.77 million Sinopharm doses arrive

Photo: Salahuddin Ahmedd/TBS
Covid-19 in Bangladesh

Over 28 lakh people inoculated on first day of Covid-19 vaccine campaign

Sinopharm has become the first non-Western vaccine that is approved by WHO. Photo: Reuters.
Coronavirus chronicle

Brazil says China's Sinopharm seeks Covid-19 vaccine emergency-use authorisation

More 20 lakh Sinopharm vaccine doses arrive in Bangladesh 
Covid-19 in Bangladesh

More 20 lakh Sinopharm vaccine doses arrive in Bangladesh 

  • Show More
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net